On August 31, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2021, which is being held from September 16-21, 2021 (Press release, Phio Pharmaceuticals, AUG 31, 2021, View Source [SID1234587047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Event:

ESMO Virtual Congress 2021

Title:

Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors

Authors:

Benjamin Cuiffo, et al.

Abstract Number:

#4154

Date:

September 16-21, 2021

An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here)